Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mike Ward
As F-star starts its transition into a clinical stage company underpinned by two proprietary bispecific compounds due to enter clinic late 2019, Eliot Forster joins the company as CEO with plans to expand the company’s regulatory and clinical operations capabilities and raise new funds.
Versant Ventures seed company Gotham Therapeutics emerges from stealth mode to develop novel class of drugs targeting RNA-modifying proteins with backing from co-leads Versant, Forbion and SR One.
European life science companies can expect to get access to almost €290m from Forbion as the EU-based venture capitalist closes its fourth fund at an oversubscribed €360m.
Following the acquisition of cell therapy assets from Sanofi, which Sanofi had secured in its purchase of Genzyme, Aastrom Biosciences changed its name to Vericel, doubled down in cell therapy and relocated to Massachusetts. Since then it has seen its revenues grow 12% per year from just under $43 million in 2013 to just under $64 million in 2017. The target for 2020: drive revenues north of $100 million.
Download this Special Report, written by Mike Ward, Head of Content for Informa Pharma Intelligence Insights Portfolio, to learn how attrition rates in oncology drug discovery and development can be improved and why a multidisciplinary approach to R&D is needed. This report includes key coverage of the Bionow’s Accelerating Cancer Drug Development - From target to patients conference, which was hosted at Alderley Park in Cheshire where its Mereside life science campus is home to some 65 SMEs and 150 start-ups, many of which work in oncology.